SEMA6B: A Potential Drug Target and Biomarker (G10501)

Target Name: SEMA6B

NCBI ID: G10501

SEMA6B

SEMA6B: A Potential Drug Target and Biomarker

Semaphorin (SEMA) genes are a family of transmembrane proteins that play a crucial role in cell signaling. The SEMA6B gene is one of the member of the SEMA gene family, and it is expressed in various tissues and organs throughout the body. SEMA6B is known to be involved in several cellular processes, including cell adhesion, migration, and invasion.

Recent studies have identified SEMA6B as a potential drug target and biomarker. SEMA6B has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting SEMA6B with small molecules or antibodies has the potential to treat these diseases.

One of the key reasons for the potential of SEMA6B as a drug target is its unique structure. SEMA6B is a transmembrane protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of SEMA6B contains a N-terminus that is involved in cell adhesion and migration. The transmembrane region of SEMA6B contains a unique protein domain that is known as the SEMA6B-type transmembrane domain (SMTD). The SMTD is a type of transmembrane domain that is characterized by the presence of a unique heparan sulfate (HS) molecule and a hydrophobic amino acid sequence.

The intracellular domain of SEMA6B contains a unique protein that is known as the SEMA6B intracellular domain (SICD). The SICD is involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. SICD contains several unique protein domains, including a short transmembrane domain (TMD), a long transmembrane domain (LTM), and a cytoplasmic domain (CPD).

SEMA6B has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, SEMA6B has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. has also been shown to play a role in the development and progression of cancer, including breast cancer and colorectal cancer.

One of the key reasons for the potential of SEMA6B as a drug target is its unique structure and its involvement in several diseases. SEMA6B is a transmembrane protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The SEMA6B-type transmembrane domain is characterized by the presence of a unique heparan sulfate (HS) molecule and a hydrophobic amino acid sequence. The SICD is involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. SEMA6B has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting SEMA6B with small molecules or antibodies has the potential to treat these diseases.

Protein Name: Semaphorin 6B

Functions: Functions as a cell surface repellent for mossy fibers of developping neurons in the hippocampus where it plays a role in axon guidance. May function through the PLXNA4 receptor expressed by mossy cell axons

The "SEMA6B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA6B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets